Biblio Discovery — Demo Discovery Service

18 results for "Dmitri Simberg"

Showing 1–18 · 0.81 seconds · RSS

  1. Journal Article Full text

    Different Kinetics of Complement Opsonization, Immune Uptake, and IL-6 Cytokine Response After Bolus Injection of Superparamagnetic Iron Oxide Nanoworms in Mice

    Yue Li; Dmitri Simberg

    Journal of Nanotheranostics, Vol. 6 No. 3 · 2025 · English · DOAJ Scopus

    Superparamagnetic iron oxide (SPIO) nanoparticles are a promising platform for drug delivery and magnetic resonance imaging (MRI). However, complement activation and immune recognition remain major barriers to their clinical translation. Previously, we reported that dextran-coated SPIO nanoworms…

  2. Journal Article

    From BioMAG® to Feraheme®: Overview of the Intellectual Property History

    Ernest Groman; Dmitri Simberg

    Precision Nanomedicine, Vol. 8 No. 4 · 2025 · English · DOAJ Scopus

    Nanomedicines advance only when scientific innovation aligns with manufacturability, regulatory expectations, and strategically constructed intellectual property. Yet the patent histories behind successful clinical nanomedicines are rarely examined, and the numerous unpublished or uncommercialized…

  3. Journal Article Full text

    Anti-Poly(ethylene glycol) (PEG) Antibodies: From Where Are We Coming and Where Are We Going

    Dmitri Simberg; S. Moein Moghimi

    Journal of Nanotheranostics, Vol. 5 No. 3 · 2024 · English · DOAJ Scopus

    PEGylation technology confers stability and modulates the biological performance of a broad range of preclinical and clinical nanopharmaceuticals. However, the emerging PEG immunogenicity in the general population is thought to impact the efficacy and safety of PEGylated medicines. Despite this…

  4. Journal Article

    Discrepancies in the in vitro and in vivo role of scavenger receptors in clearance of nanoparticles by Kupffer cells

    Dmitri Simberg; Ernest Groman; Guankui Wang

    Precision Nanomedicine, Vol. 1 No. 1 · 2018 · English · DOAJ Scopus

    Nanoparticles are recognized and cleared by Kupffer cells (KCs) in the liver. This process complicates the development of targeted nanoparticles because of significant reduction of number of nanoparticles that can reach target tissues. Macrophage scavenger receptor SR type AI/II is the central…

  5. Journal Article Full text

    How Reproducible Is Feraheme® (Ferumoxytol Injection)? Comparison of Size, Zeta Potential, and Complement Activation of Different Batches over 15 Years

    Utibeabasi Ettah; Sarah Jacques; Dmitri Simberg

    Journal of Nanotheranostics, Vol. 5 No. 3 · 2024 · English · DOAJ Scopus

    Ferumoxytol injection, also known as Feraheme®, is an approved IV injectable iron supplement and an experimental MRI contrast agent. Initially, it was approved as an IV bolus agent, but its use was later limited to a slow infusion drip due to high levels of infusion reactions. We collected various…

  6. Journal Article

    Surface Modification of Erythrocytes with Lipid Anchors: Structure–Activity Relationship for Optimal Membrane Incorporation, in vivo Retention, and Immunocompatibility

    Hanmant Gaikwad; Guankui Wang; Yue Li et al.

    Advanced NanoBiomed Research, Vol. 2 No. 8 · 2022 · English · DOAJ Scopus

    Red blood cells (RBCs) are natural carriers for sustained drug delivery, imaging, and in vivo sensing. One of the popular approaches to functionalize RBCs is through lipophilic anchors, but the structural requirements for anchor stability and in vivo longevity remain to be investigated. Using…

  7. Journal Article

    Activation of human complement system by dextran-coated iron oxide nanoparticles is not affected by dextran/Fe ratio, hydroxyl modifications and crosslinking

    Guankui Wang; Fangfang Chen; Nirmal Banda et al.

    Frontiers in Immunology, Vol. 7 · 2016 · English · DOAJ Scopus

    While having tremendous potential as therapeutic and imaging tools, the clinical use of engineered nanoparticles has been associated with serious safety concerns. Activation of the complement cascade and release of proinflammatory factors C3a and C5a may contribute to infusion-related reactions…

  8. Journal Article

    PEGylation technology: addressing concerns, moving forward

    Dmitri Simberg; Yechezkel Barenholz; Steve R. Roffler et al.

    Drug Delivery, Vol. 32 No. 1 · 2025 · English · DOAJ Scopus

    PEGylation technology, that is grafting of poly(ethylene glycol)(PEG) to biologics, vaccines and nanopharmaceuticals, has become a cornerstone of modern medicines with over thirty products used in the clinic. PEGylation of therapeutic proteins, nucleic acids and nanopharmaceuticals improves their…

  9. Journal Article

    Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking

    Lin-Ping Wu; Mario Ficker; Jørn B. Christensen et al.

    Nature Communications, Vol. 12 No. 1 · 2021 · English · DOAJ Scopus

    Understanding nanomaterials interactions with complement is important for a number of applications. Here, the authors study the interaction of sub 6 nm dendrimers with complement and show the small dendrimers escape complement activation but do interact with IgM to trigger lectin-pathway complement…

  10. Journal Article

    Cyanine lipids promote the shedding of extracellular vesicles from cell membranes

    Dmitri Simberg; Hanmant Gaikwad; David Siegel et al.

    Precision Nanomedicine, Vol. 6 No. 3 · 2023 · English · DOAJ Scopus

    Extracellular vesicles (EV) have garnered significant attention in the fields of drug delivery, imaging, and immunotherapy. There is a need in methods to enhance release of EVs from cells. We found that at high labeling concentrations (100µM), indocarbocyanine lipids DiD and DiR that are commonly…

  11. Journal Article Full text

    Isolation of Rare Tumor Cells from Blood Cells with Buoyant Immuno-Microbubbles

    Guixin Shi; Wenjin Cui; Michael Benchimol et al.

    PLoS ONE, Vol. 8 No. 3 · 2013 · English · PLOS Scopus

    Circulating tumor cells (CTCs) are exfoliated at various stages of cancer, and could provide invaluable information for the diagnosis and prognosis of cancers. There is an urgent need for the development of cost-efficient and scalable technologies for rare CTC enrichment from blood. Here we report…

    Also available at: DOAJ

  12. Journal Article

    Lipid nanoparticle formulation of niclosamide (nano NCM) effectively inhibits SARS-CoV-2 replication in vitro

    Guankui Wang; Hanmant Gaikwad; Mary McCarthy et al.

    Precision Nanomedicine, Vol. 4 No. 1 · 2021 · English · DOAJ Scopus

    As exemplified by the COVID-19 pandemic, highly infectious respiratory viruses can spread rapidly in the population because of a lack of effective approaches to control viral replication and spread. Niclosamide is an old anthelminthic drug (see the essential medicine list of the World Health…

  13. Journal Article

    C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice

    Nirmal K. Banda; Stephen Tomlinson; Robert I. Scheinman et al.

    Frontiers in Immunology, Vol. 11 · 2020 · English · DOAJ Scopus

    Natural IgM antibodies (NAbs) have been shown to recognize injury-associated neoepitopes and to initiate pathogenic complement activation. The NAb termed C2 binds to a subset of phospholipids displayed on injured cells, and its role(s) in arthritis, as well as the potential therapeutic benefit of a…

  14. Journal Article

    Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models

    Bin Zhang; Amy B Heimberger; Irina V Balyasnikova et al.

    Journal for ImmunoTherapy of Cancer, Vol. 13 No. 10 · 2025 · English · DOAJ Scopus

    Background Bispecific T cell-engagers (BTEs) are engineered antibodies that redirect T cells to target antigen-expressing tumors. BTEs targeting tumor-specific antigens such as interleukin 13 receptor alpha 2 (IL13RA2) and epidermal growth factor receptor variant III (EGFRvIII) have been developed…

  15. Journal Article

    Analysis of human factor H-related gene and protein expressed in rheumatoid arthritis synovium identifies a novel mechanism promoting dysregulated complement pathway activation

    Nirmal K. Banda; Larry W. Moreland; Kevin D. Deane et al.

    Scientific Reports, Vol. 15 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Factor H (FH) is a negative regulator of the alternative pathway (AP) of complement however, five human factor H-related (FHR) proteins, can also function ex vivo as positive regulators. We compare bulk FH and FHR mRNA expressions in both the human rheumatoid arthritis (RA) synovium and…

  16. Journal Article

    Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors

    Joseph T. Duffy; Angela Martin‐Regalado; Benedikt E. Haupt et al.

    Advanced Science, Vol. 13 No. 35 · 2026 · English · DOAJ Scopus

    ABSTRACT Bispecific T cell engagers (BTEs) induce MHC‐independent cytotoxicity by bridging T cells to tumor cells via binding a T cell–activating receptor and a tumor‐associated antigen. BTEs have proven effective in hematologic malignancies and some solid tumors, yet their potential in…